Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 8/20 | 0.34 |
| ▸ | DNM2 | P50570 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 7/20 | 0.32 |
| ▸ | ELOVL1 | Q9BW60 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20122627 | 0.84 | DNM2 (0.34) | DNM2CYP1A2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL23768206 | 0.75 | DNM2 (0.40) | DNM2CYP1A2CYP2D6ALDH1A1CYP3A4 | |
| SCHEMBL19135622 | 0.73 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL21784451 | 0.69 | CYP2D6 (0.41) | CNR2CYP2D6CYP3A4CNR1 | |
| SCHEMBL20877706 | 0.68 | CNR2 (0.40) | CNR2CYP2D6CYP3A4CNR1 | |
| SCHEMBL19135617 | 0.68 | CNR2 (0.46) | CNR2CNR1 | |
| SCHEMBL22601534 | 0.66 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL23809442 | 0.65 | CNR2 (0.41) | CNR2CNR1 | |
| SCHEMBL23743834 | 0.65 | CNR2 (0.43) | CNR2CNR1 | |
| SCHEMBL19254601 | 0.65 | CNR2 (0.42) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2020-07-14 | — | — | US | disclosed |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10709712-B2 | Biaryl amide compounds as kinase inhibitors | BRAF, RAF1, NRAS | CNR2 1910/4885DNM2 2385/4885CYP1A2 1317/4885 |
| US-20190175606-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | CNR2 1910/4885DNM2 2385/4885CYP1A2 1317/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.